Overview

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Status:
Unknown status
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
Phase:
Phase 1
Details
Lead Sponsor:
Cyclacel Pharmaceuticals, Inc.
Collaborator:
M.D. Anderson Cancer Center